glp-1 for mental health Not an 'Easy Way Out': How Users Navigate the Stigma of Weight Loss Drugs The Impact of GLP-1 Receptor

Doi:10.1056/NEJMoa2404881 Pi-Sunyer X, Astrup A, Fujioka K, et al

Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, Lau ESH, Eliasson B, Kong APS, Ezzati M, Aguilar-Salinas CA, McGill M, Levitt NS, Ning G, So WY, Adams J, Bracco P, Forouhi NG, Gregory GA, Guo J, Hua X, Klatman EL, Magliano DJ, Ng BP, Ogilvie D, Panter J, Pavkov M, Shao H, Unwin N, White M, Wou C, Ma RCW, Schmidt MI, Ramachandran A, Seino Y, Bennett PH, Oldenburg B, Gagliardino JJ, Luk AOY, Clarke PM, Ogle GD, Davies MJ, Holman RR, Gregg EW

Compounded drugs are not reviewed or approved by the FDA as safe and effective (U.S

Over 52 weeks, the apnea-hypopnea index (AHI) decreased by 25,3 events per hour in the tirzepatide arm without CPAP (vs

Metformin retards aging in C

Rather than acting solely through weight loss or peripheral glucose control, GLP-1 therapies engage neural pathways involved in energy regulation, inflammation, synaptic integrity, and protein homeostasisoffering a biologically coherent explanation for their emerging association with preserved cognitive function and reduced dementia risk